home About Us People Portfolio News Contact Us Fund I Investor Login » Fund II Investor Login » Fund III Investor Login »

news

Feb20Dynavax Secures $175 Million in Non-Dilutive Debt Financing »


-- Proceeds to be Used to Commercialize HEPLISAV-B™ [Hepatitis B Vaccine (Recombinant), Adjuvanted] in United States and Advance Company's Immuno-Oncology Product Candidates --   -- Company Deploying HEPLISAV-B...

Read More »

Feb12Viveve Announces Closing of Public Offering of Shares of Common Stock »


Englewood, CO -- (Marketwired) -- 02/12/18 -- Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced the closing of its previously...

Read More »

Feb9Tandem Diabetes Care Announces Pricing of $60 Million Underwritten Public Offering of Common Stock »


San Diego --(BUSINESS WIRE) --Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today...

Read More »

Jan25Synergy Pharmaceuticals Announces FDA Approval of TRULANCE® (Plecanatide) for the Treatment of Irritable Bowel Syndrome with Constipation (IBSC) in Adults »


NEW YORK- (BUSINESS WIRE)-- Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced today that the U.S. Food and Drug Administration (FDA) has approved TRULANCE ®(plecanatide) 3 mg tablet for the...

Read More »

Jan25Strongbridge Biopharma plc Announces Pricing of Public Offering of Ordinary Shares »


Dublin, Ireland and Trevose, Pa., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ:SBBP) (the “Company”) today announced that it has priced its...

Read More »

Jan17Strongbridge Biopharma plc Announces Acquisition of the U.S. and Canadian Rights to MACRILEN™ (macimorelin) from Aeterna Zentaris »


-- MACRILEN is the First and Only FDA-Approved Oral Drug Indicated For the Diagnosis of Adult Growth Hormone Deficiency, a Rare Endocrine Disorder -- -- MACRILEN is Strongbridge...

Read More »

Dec19Synergy Pharmaceuticals Appoints Troy Hamilton Chief Executive Officer »


-- Co-Founder Gary S. Jacob, Ph.D., Named Executive Chairman  --   New York - (BUSINESS WIRE) -- Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on...

Read More »

Dec6TearLab Prices $3.0 Million Registered Direct Offering »


San Diego, Dec. 06, 2017 (GLOBE NEWSWIRE) -- TearLab Corporation (OTCQB:TEAR) (TSX:TLB) (“TearLab” or the “Company”), today announced the pricing of a registered direct offering of 6,818,182...

Read More »

Nov28CRG Provides Investment Update, Committing $881 Million of New Capital to Healthcare Investments Over the Last 12 Months »


-- Continues momentum executing growth capital investment strategy to commercial-stage healthcare companies --   Boulder, Colo. – November 28, 2017 – CRG, a preeminent healthcare-focused investment firm, today announced cumulative financing commitments...

Read More »

Oct24NeuroPace Closes $74 Million Equity Funding to Accelerate Patient Access to the World’s First Brain-Responsive Neurostimulation System to Treat Epilepsy »


Mountain View, Calif. – October 24, 2017 – NeuroPace, Inc., a Silicon Valley-based medical technology company that developed the world’s first and only closed-loop brain-responsive neurostimulation system shown to...

Read More »

Oct24ViewRay Raises $50 Million through Sale of Common Stock »


-- Financing to Support Ongoing Commercialization of MRIdian Linac --   Cleaveland, Oct. 24, 2017 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), maker of the world's first and only clinical MRI-guided...

Read More »

Oct4Strongbridge Biopharma plc Announces Pricing of Public Offering of Ordinary Shares »


Dublin, Ireland and Trevose, Pa., Oct. 04, 2017 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ:SBBP) (the “Company”) today announced that it has priced...

Read More »

Sep14GenomeDx to Distribute Pathnostics’ Guidance UGx Test for Urinary Tract Infection and Guidance PRx Test for Prostatitis »


-- Strategic Agreement Accelerates GenomeDx’s Product Expansion in Urologic Genomics --   San Diego and Irvine, CA – September 14, 2017 – GenomeDx Biosciences, a leader in the...

Read More »

Sep5Synergy Pharmaceuticals Secures $300 Million Debt Financing »


New York, September 5, 2017 --Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), announced today that the Company has closed on a $300 million debt financing structured as senior secured loans from CRG LP, a...

Read More »

Jul31CRG's Third Healthcare Fund Closes $355 Million Term Loan Securitization »


Houston – July 31, 2017 – CRG, a premier healthcare-focused investment firm, today announced the closing of a $355 million term loan securitization on behalf of CRG Partners III, L.P. and certain...

Read More »
Load More